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Purpose: An expansion of selection criteria for deceased organ transplantation already 
exists to manage the current donor shortage. Comparable evaluation of risk factors for living 
donors should be investigated to improve this issue.
Patients and Methods: Our retrospective single-centre study analysed 158 patients with 
living kidney transplants performed between February 2006 and June 2012. We investigated 
the influence of donor risk factors (RF) including body mass index over 30 kg/m2, age >60 
years, active nicotine abuse and arterial hypertension on postoperative kidney function with 
focus on the recipients. This was measured for long-term survival and glomerular filtration 
rate (GFR) in a 5-year follow-up.
Results: Overall, out of 158 living donors, 84 donors were identified to have no risk factors, 
whereas 74 donors had at least one risk factor. We noted a significant higher delayed 
graft function (p=0.042) in the first 7 days after transplantation, as well as lower GFR of 
recipients of allografts with risk factors in the first-year after transplantation. In our long-term 
results, there was no significant difference in the functional outcome (graft function, recipient 
and graft survival) between recipients receiving kidneys from donors with no and at least one risk 
factors. In the adjusted analysis of subgroups of different risk factors, recipients of donors with 
“age over 60 years” at time of transplantation had a decreased transplant survival (p=0.014).
Conclusion: Thus, a careful expansion for selection criteria for living donors with critical 
evaluation could be possible, but especially the age of the donors could be a limited risk 
factor.
Keywords: living donor nephrectomy, risk factor, selection criteria, survival, GFR
Introduction
Kidney transplantation is still the best option for patients with end stage kidney 
disease (ESKD) as patient survival rates are higher after kidney transplantation in 
comparison to patients remaining on dialysis.1 Furthermore, patients on dialysis 
have a threefold higher death rate and a more than sevenfold higher cardiovascular 
death rate compared to patients who received a kidney transplant.2
These risks must be evaluated in the context of further increasing waiting list in 
Germany. In 2018, 2.291 kidney transplantations were performed including 638 
living donations (38.6%). Furthermore, approximately 7.500 patients diagnosed 
with ESKD are currently on the waiting list for an organ donation in Germany.3
Organ transplantation after living donor nephrectomy (LDN) is one option in 
order to reduce the waiting time for a deceased organ and offers the access to 
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transplantation. Furthermore, the outcome of living dona-
tion is better in contrast to deceased donation.4,5 To fulfill 
the requirements of living organ donation, patients need 
to have reached the legal age of 18 years to give volun-
tary consent and have the mental capacity to comprehend 
the risks and consequences of organ donation.6 For older 
patients, donor age alone is no absolute contraindication 
for an organ donation, but the donor should have at least 
a glomerular filtration rate (GFR) of 80mL/min. 
Currently, the following contraindications for LDN 
include diabetes mellitus, uncontrolled hypertension, pro-
teinuria >300mg/24 h, age under 18 years, and a high 
risk for a thromboembolic event [5]. Contraindications 
include body mass index (BMI) >35kg/m2, unsteady 
chronic infections including tuberculosis, hepatitis, and 
other mental health diseases, as well as microhaematuria 
without renal disease.7,8 Within the past decade, donor 
inclusion criteria have been adjusted to manage the dis-
parity between organ supply and demand. These changes 
included age adjustments for deceased donors over the 
age of 60 years or over 50 years of age diagnosed with 
hypertension and reduced renal function with serum crea-
tinine levels over 1.5 mg/dl.9,10 In 1999, Eurotransplant 
established the European Senior Transplant Program 
matching donors and recipients over 65 years of age. 
Fabrizii et al demonstrated that the use of kidneys with 
suboptimal quality from “marginal” donor demonstrated 
a comparable short- and long-term outcome for the 
recipients.11 Accordingly, a similar expansion of selection 
criteria for living transplantation, also known as 
expanded-criteria living donors (ECLDs), could improve 
access for many patients diagnosed with ESKD.12 ECLDs 
should consider donor age, GFR, BMI, impaired glucose 
tolerance and smoking history. Moreover, in living 
donors the kidneys vascular supply could influence reci-
pients’ outcome.13 A detailed evaluation of these risk 
factors and comorbidities is therefore essential to main-
tain donor safety as the mentioned risk factor are asso-
ciated with increased rates of perioperative nephrectomy 
complications.14 Furthermore, extended criteria should 
not impair the outcome and graft function for the recipi-
ent. As there is little information available regarding the 
influence of extended criteria, this study aims to evaluate 
the influence of different ECLDs on the recipients’ out-
come following living kidney transplantation.
Patients and Methods
Patients and Study Design
This retrospective analysis utilized data from our institu-
tional electronic database (TBase©) of LDN at Charité 
Universitaetsmedizin Campus Mitte (Berlin, Germany) 
between February 2006 and June 2012. Paediatric LDN 
were excluded from this study. Data were collected and 
approved according to the guidelines of the institutional 
review board “Ethikkomission Charité” (Berlin, Germany) 
which based on the ICH Guideline for Good Clinical 
Practice and the declaration of the World Medical 
Association from 1964 (Helsinki) in their current version. 
Patient consent for review of medical records was not 
required because all data were de-identified. Therefore, 
all patient data were treated anonymously.
All living kidney donations were conducted voluntarily 
with a written informed consent of the donor in accor-
dance to the Declaration of Istanbul before surgery. Every 
donor and recipient agreed for lifetime aftercare recording 
medical records in the electronic TBase© System for 
research. Our previous study describes the preoperative 
evaluation of living donors, the surgical techniques includ-
ing laparoscopic approach via a 4-port transperitoneal 
access and our immunosuppression regime.13
Outcome Parameters
Donors were divided in two groups: donors without risk 
factors (RF) and donors with at least one RF. RF were 
defined as age over 60 years, arterial hypertension, active 
nicotine abuse and BMI over 30kg/m2. Operation details 
were measured surgery time, warm and cold ischemia and 
HLA mismatch.
Outcome parameters for both groups included post-
operative GFR in mL/min, delayed graft function (DGF), 
graft function (GF) and graft- and patient survival. The 
DGF was suspected if haemodialysis was required within 
seven days postoperatively.15 GF was assessed by serum- 
creatinine, GFR and rejection rate after transplantation.
Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics 
22 for Mac (SPSS, Inc., Chicago, IL, USA). Univariate 
parameters were analysed by χ2-Test and Fisher-Test. 
Continuous variables were tested with the non-paired 
Student’s t-Test and the Mann–Whitney U-test for data with 
non-normal distribution. Kaplan-Meier estimates were used 
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to calculate patient and transplant survival curves. We 
excluded all cases of recipients deceased with a functional 




Overall, 158 living donor transplantations were performed 
between February 2006 and June 2012. One hundred 
forty-nine cases (94.3%) had a primary transplantation, 
nine (5.7%) cases a second transplantation and 
23 (14.6%) transplantations were performed prior to dia-
lysis. In total, n=84 donors had no RF, whereas n=74 
donors had at least one or more RF with a mean follow- 
up of 33 months. The patient characteristics between 
donor groups are depicted in Table 1 and the recipient 
characteristics in Table 2. As shown in Table 1 there was 
no significant difference between the two groups in terms 
of time of donor nephrectomy, cold/warm ischemia time, 
HLA mismatch.
Functional Outcome
Among recipients of allografts with RF we detected 
a higher Delayed Graft Function in the first 7 days of 
transplantation (Table 1) with 12.1% in group with RF 
vs 3.6% with RF (p=0.042) Although the recipients of 
kidneys from optimal donors had a significant higher 
GFR in the first-year post-transplantation, no significant 
difference was observed in the following years 
(Figure 1).
Figure 2 shows an adjusted analysis of post-operative 
GFR rates of recipients from allografts from donors with 
various risk factors three months after surgery. Only the 
group “Age over 60 years” had a significant reduced renal 
function (p<0.001).
During the follow up time, 50 recipients were identified 
to have a rejection in a biopsy result (32.3%), however no 
difference was detected between the two study groups (donor 
group without RF n=24, donor group with RF n=26, 
p=0.453). Overall graft survival of both groups was 93% 
without a significant difference between both groups 
(p=0.552) (Figure 1 Supplementary material). Only the sub-
group of recipients of allografts from donors with “Age over 
60 years” had a decreased graft survival with 75% in the 
follow up period compared to 94% in the group without RF 
(p=0.014) (Figure 2 Supplementary material). The overall 
survival of the recipients of the two groups with and without 
RF in the maximum follow up period of 76 months was 
97.4% (p=0.232) (Figure 3 Supplementary material). The 
cause of death (n=1) in the group without RF was a brain 
oedema ten days after transplantation. The causes of death 
(n=3) in the group with RF were cardiac arrest, infection and 
cancer.
Discussion
In the present retrospective study, we found no difference 
in the functional outcome (graft function, survival) for the 
recipients receiving kidneys from donors without or with 
Table 1 Means of Demographic Donor Characteristics and 
Operation Details
Variables Donor without 
RF n=84
Donor with RF 
n=74
P-value
Age, years (SD) 45.4 (24–60) 55.9 (21–78) 0.0000*
Gender, Male 23 (27.4%) 29 (39.2%) 0.115
BMI, kg/m2 (SD) 24.2 (17.6–30.0) 26.7 (18.0–37.3) 0.0003*
Risk factors
Age > 60 years – 34 (21.7%)
Arterial Hypertonus – 20 (12.7%)
BMI > 30 kg/m2 – 22 (13.9%)
Active nicotine abuse – 21 (13.3%)
Vascularization
Number Arteries 0.512
1 66 (78.6%) 60 (71.4%)
≥1 15 (17.9%) 13 (17.6%)
Unknown 2 (2.4%) 1 (1.3%)
Number Veins 0.123
1 75 (89.3%) 71 (95.9%)
2 7 (8.3%) 2 (2.7%)
Unknown 2 (2.4%) 1 (1.3%)
Operation 
Characteristics
Time of Surgery 
nephrectomy (min)
210.5 203.6 0.474
Warm ischemia time 
(min)
2.48 2.46 0.902
Cold ischemia time (h) 2.62 2.77 0.1608
HLA-Mismatch
MM-A (SD) 0.88 (0.12–1.6) 0.84 (0.12–1.56) 0.700
MM-B (SD) 1.13 (0.35–1.83) 1.11 (0.5–1.72) 0.756
MM-DR (SD) 0.98 (0.30–1.66) 0.97 (0.33–1.65) 0.987
MM total (SD) 2.99 (1.36–4.62) 2.92 (1.40–4.50) 0.678
DGF (SD) 3 (3.6%) 9 (12.1%) 0.042*
Notes: *Indicates P-values <0.05. 
Abbreviations: RF, risk factor; n, number; BMI, body mass index; min, minutes; h, 
hours; SD, standard deviation; HLA, human leukocyte antigen; MM-A, mismatch 
Loci A; MM-B, mismatch Loci B; MM-DR, mismatch Loci DR; DGF, delayed graft 
function.
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risk factor in general. Although in the first years after 
transplantation the GFR was significantly reduced among 
recipients of allografts from donors with RF, after 2 years 
the results were comparable. Nevertheless, in the subana-
lysis of graft survival outcome in subgroup risk factor 
“Age over 60 years” we found a statistical difference 
with a better functional outcome for recipient of allografts 
from younger living donors.
The topic of age remains always controversial as 
age alone should not be an absolute contraindication 
for organ donation. Nevertheless, a correlation between 
age and higher rates of comorbidities exists. An 
adverse effect of advanced donor age for allograft 
survival is already described for deceased organ 
transplantation.16 In a follow-up of five years 
Iordanous et al showed in their meta-analysis of 31 stu-
dies of living kidney donation a poorer outcome for 
graft survival in the group of donors aged over 
60 years compared to younger donors.17 In contrast to 
these results, there are the promising findings in the 
European Senior Transplant Program, which allocated 
organs of donors over the age of 65 with end stage 
renal disease without an impairment of the survival or 
graft function.11 A recent review supports these results 
with an adequate outcome for older recipients, whereas 
younger patients with ESKD benefit from a younger 
LDN.18 The definition of “old” in the existing studies 
of ECLDs is unequal for the donors as the cut off 
differs between over 40 years up to 65 years of ages 
limiting their comparability.
Kidney transplantation of obese donors had no nega-
tive effect on renal graft function in our study. In 2000, 
Jacobs et al reported that the laparoscopic nephrectomy 
for obese patients with a mean BMI of 39kg/m2 is 
associated with more difficulties during surgery but had 
the same results in the recovery and graft function.14 
Interestingly, results from the analysis of surgical- and 
ischemia time, showed no difference between donors 
with or without obesity (BMI ≥ 30kg/m2) as the technical 
circumstances of the nephrectomy itself were similar. 
This underlines the experiences of recent studies.19 
After nephrectomy, the aftercare of obese donors is cru-
cial, because these patients have an increased lifetime 
risk for developing ESKD.20,21 Even with normal pre- 
donation graft function, each kidney donor has a potential 
risk of developing chronic renal disease of at least stage 
one based on the classification of KDGIO 2012.22 Locke 
et al described that each unit of a pre-donation BMI 
above 27 kg/m2 was associated with a seven percent 
higher risk of ESKD post-donation.23 Due to the lack 
of follow-up data of the donors, long-term renal function 
in these patients is unclear.
One of the most common cause of mortality of chronic 
renal failure is cardiovascular diseases, which could be 
influenced by the risk factors including hypertension and 
active nicotine abuse.
Smoking tobacco is one of the most common drugs 
abused by a mean rate of 25% in the German population.24 
Although we did not verify an impairment on graft-or 
recipient survival, its negative effects can be found in the 
literature.25 Heldt et al showed a dose-dependent relation-
ship between tobacco exposure and renal graft function. 
They showed a direct correlation between high level of 
tobacco exposure and reduced renal graft function by 
measuring post-donation GFR at one and six months post- 
transplantation in organ recipients. Other demographic 
characteristics including age, BMI and comorbidities 
such as hypertension and diabetes were equal. 
Nevertheless, our findings must be interpreted carefully, 
as dosing of donor tobacco use were not determined in our 
study but supposed to be relevant.
Table 2 Recipients Characteristics in Means, Percentage and 
Standard Deviation
Variables Recipient n=158
Age, Year (SD) 43.6 (29–58)
Gender, Male n (%) 105 (66.4)
BMI, kg/m2 (SD) 24.6 (19.8–29.7)
Cause of ESKD
Diabetes, n (%) 4 (2.5)
Art. Hypertonus, n (%) 11 (7)
Glomerulonephritis, n (%) 25 (15.8)
Polycystic renal disease, n (%) 30 (19)
Congenital uropathy, n (%) 10 (6.3)
IgA Nephropathy, n (%) 25 (15.8)
FSGS, n (%) 9 (5.7)
Other, n (%) 44 (27.8)
Dialysis
No Dialysis, n (%) 23 (14.6)
Haemodialysis, n (%) 59 (37.3)
Peritoneal dialysis, n (%) 10 (6.3)
Unknown, n (%) 66 (41.8)
Duration of Dialysis, Months (SD) 18 (3–33)
Abbreviations: n, number; ESKD, end stage kidney disease; SD, standard devia-
tion; IgA, immunoglobulin A; FSGS, focal segmental glomerulosclerosis.
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Donors diagnosed with arterial hypertension with 
blood pressures over 140/90 mmHg are meant to be sub-
optimal for LDN according to the Amsterdam Forum.6 We 
assigned all donors with at least one blood pressure med-
ication to the group with risk factors without further con-
sideration. According to the results of the review of 
Iordanous et al considering similar selection criteria for 
arterial hypertension, we could not determine a negative 
impact on graft function.17 Both of the two mentioned 
studies in the review analysed the post-donation GFR 
and showed a comparable function in the recipient 
one year post-transplantation in the optimal and subopti-
mal donor group.26,27 Regarding the long-term effects on 
blood pressure of the donor, our findings are limited as the 
focus is on the recipients graft survival. The evaluation of 
the cardiovascular risks of living donors are estimated 
variables based on literature. Some studies detected higher 
prevalence of hypertension up to 150% compared to the 
control group,28,29 whereas other research did not identify 
relevant differences.30,31 Based on a more frequent mon-
itoring post-LDN, higher prevalence of hypertension in the 
donor groups could be expected.
However, our study must be interpreted in the context of its 
limitations. Our data supports existing research and efforts of 
improving living kidney donation but do not confirm 
a harmless expansion of selection. The small population and 
a mean follow up of 33 months after transplantation may not 
allow identifying long-term effects of expanded criteria for 
donors. Concerning this matter Muzaale et al showed 2016 
their 20-year follow up those donor-dependent subclinical risk 
factors for ESKD as hypertension or age could jeopardize the 
graft survival.21 By dichotomizing the extended criteria (with 
RF/without RF), potential confounding of the risk factors is 
maybe neglected and should be further analysed.
Conclusion
Finally, our findings demonstrated a worse graft function 
of allografts from high-risk donors in the first year. In the 
long-term results, only the group of age over 60 had 
a negative impact in graft survival. Thus, an expansion 
of criteria for living kidney donors may improve the cur-
rent lack of organs, however a preoperative evaluation and 
allocation of donors and recipients is absolute essential. As 
we have focussed on the recipient’s outcome it is equally 
Figure 1 Postoperative Follow up of renal function of the recipients after transplantation.  
Note: *Indicates P-values <0.05.  
Abbreviations: GFR, glomerular filtration rate; RF, risk factor; w, week; m, months; y, years.
Dovepress                                                                                                                                                            Plage et al
Therapeutics and Clinical Risk Management 2020:16                                                                    submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       









































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
necessary to evaluate the impact for the donor and poten-
tial risks for ESKD in further research.
Disclosure
The authors report no conflicts of interest in this work.
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